ClinicalTrials.gg
Active, not recruitingNCT04857034Updated Sep 10, 2025Results posted

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

A Phase 2 interventional study of Deucravacitinib and Placebo in Lupus Erythematosus, Discoid and Lupus Erythematosus, Subacute Cutaneous, sponsored by Bristol-Myers Squibb. Active, not recruiting at 41 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Lupus Erythematosus, Discoid with a site in United States — 5 open to participants now, 10 under way, 7 of them phase 3. Lupus Erythematosus, Discoid · United States.

Enrollment
10th of 27
74 · median 48
Started
2021
the only one that year
Phase 2
14 of 31
none open now
Registered
18th of 31
by date
Lead sponsor
2 of 31
Bristol-Myers Squibb

Among the 31 studies in Lupus Erythematosus, Discoid with a site in United States, this one is the 10th largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2021, is one of 14 in phase 2, and was the 18th registered.

Lupus Erythematosus, Discoid

42 studies on the registry are indexed under Lupus Erythematosus, Discoid; 7 are open to participants now.

Browse Lupus Erythematosus, Discoid studies →

Open to participants now

5 of the 31 studies in Lupus Erythematosus, Discoid with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Lupus Erythematosus, Discoid studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Lupus Erythematosus, Discoid with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, efficacy, and tolerability of deucravacitinib (BMS-986165) compared with placebo in participants with active discoid and/or subacute cutaneous lupus erythematosus (DLE/SCLE). This study will also assess if deucravacitinib is biologically active and potentially effective in the treatment of participants with moderate to severe DLE/SCLE with or without systemic lupus erythematosus (SLE) that is not well controlled with standard of care therapy.

03

Conditions studied

  • Lupus Erythematosus, Discoid
  • Lupus Erythematosus, Subacute Cutaneous

Keywords

  • BMS-986165
  • Deucravacitinib
  • DLE
  • Discoid Lupus Erythematosus
  • SCLE
  • Subacute Cutaneous Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of discoid/subacute cutaneous lupus erythematosus (DLE/SCLE) for at least 3 months prior to screening visit
  • Meets both clinical and histopathological diagnostic cutaneous lupus erythematosus (CLE) criteria per protocol
  • Currently receiving treatment for DLE/SCLE with a stable regimen of at least one of the following medications: oral , and/or antimalarial, and/or
  • Participant could be with or without concurrent systemic lupus erythematosus (SLE)
  • If participant receives nonsteroidal anti-inflammatory drugs (NSAIDs) or analgesics treatment then the participant must be on a stable dose 2 weeks prior to screening

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant, lactating, breastfeeding or planning pregnancy during the study period
  • Any of the following specific CLE subtypes in isolation: acute cutaneous lupus erythematosus (ACLE), lupus tumidus, lupus (profundus) panniculitis, chilblains
  • Drug-induced CLE and/or drug-induced systemic lupus erythematosus (SLE)
  • Antiphospholipid antibody syndrome, serious thrombotic event or unexplained pregnancy loss within 1 year before the screening visit
  • History of 3 or more unexplained consecutive pregnancy losses
  • Active severe or unstable neuropsychiatric SLE
  • Other diseases or non-SLE driven inflammatory joint or skin disease or overlap syndromes as primary disease that in the opinion of the investigator will significantly impact the assessment of CLE/SLE disease manifestations and activity

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Active Treatment: Deucravacitinib Dose 1

    Drug: Deucravacitinib

  • Experimental
    Active Treatment: Deucravacitinib Dose 2

    Drug: Deucravacitinib

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Specified dose on specified days

  • DrugPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline in CLASI Activity Score at Week 16

    The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated clinical tool designed to assess skin involvement in cutaneous lupus erythematosus (CLE). It separately scores: * Disease activity (e.g., erythema, scale, mucous membrane involvement, alopecia) * Damage (e.g., dyspigmentation, scarring) CLASI enables classification of disease severity: Mild: Activity score 0-9 Moderate: 10-20 Severe: 21-70

    Time frame: From first dose to Week 16 (approximately 16 weeks)

Secondary outcomes

  1. Percentage of Participants With an Improvement of ≥ 50% From Baseline in the CLASI-A Score (CLASI-50).

    The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated clinical tool designed to assess skin involvement in cutaneous lupus erythematosus (CLE). It separately scores: * Disease activity (e.g., erythema, scale, mucous membrane involvement, alopecia) * Damage (e.g., dyspigmentation, scarring) CLASI enables classification of disease severity: Mild: Activity score 0-9 Moderate: 10-20 Severe: 21-70

    Time frame: From first dose to Week 16 (approximately 16 weeks)

  2. Percentage of Participants Who Have Disease Improvement as Defined by a Reduction in CLASI-A of ≥ 4 Points From Baseline.

    The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated clinical tool designed to assess skin involvement in cutaneous lupus erythematosus (CLE). It separately scores: * Disease activity (e.g., erythema, scale, mucous membrane involvement, alopecia) * Damage (e.g., dyspigmentation, scarring) CLASI enables classification of disease severity: Mild: Activity score 0-9 Moderate: 10-20 Severe: 21-70

    Time frame: From first dose to Week 16 (approximately 16 weeks)

  3. Mean Change From Baseline in CLASI-A Score.

    The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated clinical tool designed to assess skin involvement in cutaneous lupus erythematosus (CLE). It separately scores: * Disease activity (e.g., erythema, scale, mucous membrane involvement, alopecia) * Damage (e.g., dyspigmentation, scarring) CLASI enables classification of disease severity: Mild: Activity score 0-9 Moderate: 10-20 Severe: 21-70

    Time frame: From first dose to Week 16 (approximately 16 weeks)

  4. Percentage of Participants Who Have a Complete Response (CR) on CLASI-A Defined as a Score of "0".

    The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated clinical tool designed to assess skin involvement in cutaneous lupus erythematosus (CLE). It separately scores: * Disease activity (e.g., erythema, scale, mucous membrane involvement, alopecia) * Damage (e.g., dyspigmentation, scarring) CLASI enables classification of disease severity: Mild: Activity score 0-9 Moderate: 10-20 Severe: 21-70 Complete Response (CR) on CLASI-A defined as a score of "0".

    Time frame: From first dose to Week 16 (approximately 16 weeks)

  5. Number of Participants With Safety Related Events in the Placebo Controlled Period

    Number of participants with safety related events in the placebo controlled period

    Time frame: From signing informed consent to end of safety follow up period (Approximately 60 weeks)

  6. Number of Participants With Safety Related Events in the Active Treatment Period

    Number of participants with safety related events in the active treatment period

    Time frame: From signing informed consent to end of safety follow up period (Approximately 60 weeks)

  7. Number of Participants With Clinically Significant Laboratory Abnormalities in the Placebo Controlled Period

    Number of participants with clinically significant laboratory abnormalities in the placebo controlled period

    Time frame: From signing informed consent to end of safety follow up period (Approximately 60 weeks)

  8. Number of Participants With Clinically Significant Laboratory Abnormalities in the Active Treatment Period

    Number of participants with clinically significant laboratory abnormalities in the active treatment period

    Time frame: From signing informed consent to end of safety follow up period (Approximately 60 weeks)

  9. Number of Participants With Clinically Significant Vital Sign Abnormalities in the Placebo Controlled Period

    Number of participants with clinically significant vital sign abnormalities in the placebo controlled period

    Time frame: From signing informed consent to end of safety follow up period (Approximately 60 weeks)

  10. Number of Participants With Clinically Significant Vital Sign Abnormalities in the Active Treatment Period

    Number of participants with clinically significant vital sign abnormalities in the active treatment period

    Time frame: From signing informed consent to end of safety follow up period (Approximately 60 weeks)

  11. Number of Participants With Clinically Significant ECG Abnormalities in the Placebo Controlled Period

    Number of participants with clinically significant ECG abnormalities in the placebo controlled period

    Time frame: From signing informed consent to end of active treatment period (Approximately 56 weeks)

  12. Number of Participants With Clinically Significant ECG Abnormalities in the Active Treatment Period

    Number of participants with clinically significant ECG abnormalities in the active treatment period

    Time frame: From signing informed consent to end of active treatment period (Approximately 56 weeks)

07

Results

Posted Sep 10, 2025

Participant flow

Placebo-Controlled Period
Participant flow — Placebo-Controlled Period
MilestonePlacebo-Controlled Period: Treatment 1Placebo-Controlled Period: Treatment 2Placebo-Controlled Period: PlaceboActive-Treatment Period: Treatment 1Active-Treatment Period: Treatment 2
Started25252400
Completed21202200
Not completed45200
Withdrew: Request to discontinue22000
Withdrew: Withdrew consent11200
Withdrew: Pregnancy11000
Withdrew: Ongoing study period01000
Active Treatment Period
Participant flow — Active Treatment Period
MilestonePlacebo-Controlled Period: Treatment 1Placebo-Controlled Period: Treatment 2Placebo-Controlled Period: PlaceboActive-Treatment Period: Treatment 1Active-Treatment Period: Treatment 2
Started1620099
Completed119056
Not completed511043
Withdrew: Lack of efficacy10000
Withdrew: Request to discontinue01010
Withdrew: Administrative reason by sponsor15022
Withdrew: Other reasons11001
Withdrew: Ongoing study period24010

Outcome measures

PrimaryPercentage Change From Baseline in CLASI Activity Score at Week 16

The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated clinical tool designed to assess skin involvement in cutaneous lupus erythematosus (CLE). It separately scores: * Disease activity (e.g., erythema, scale, mucous membrane involvement, alopecia) * Damage (e.g., dyspigmentation, scarring) CLASI enables classification of disease severity: Mild: Activity score 0-9 Moderate: 10-20 Severe: 21-70

Time frame:
From first dose to Week 16 (approximately 16 weeks)
Reported as:
Mean · Percentage change from baseline
Percentage Change From Baseline in CLASI Activity Score at Week 16
Percentage change from baselinePlacebo-Controlled Period: Treatment 1Placebo-Controlled Period: Treatment 2Placebo-Controlled Period: Placebo
Percentage Change From Baseline in CLASI Activity Score at Week 16-48.56 ± 44.684-48.93 ± 33.302-27.31 ± 29.716
SecondaryPercentage of Participants With an Improvement of ≥ 50% From Baseline in the CLASI-A Score (CLASI-50).

The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated clinical tool designed to assess skin involvement in cutaneous lupus erythematosus (CLE). It separately scores: * Disease activity (e.g., erythema, scale, mucous membrane involvement, alopecia) * Damage (e.g., dyspigmentation, scarring) CLASI enables classification of disease severity: Mild: Activity score 0-9 Moderate: 10-20 Severe: 21-70

Time frame:
From first dose to Week 16 (approximately 16 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With an Improvement of ≥ 50% From Baseline in the CLASI-A Score (CLASI-50).
Percentage of participantsPlacebo-Controlled Period: Treatment 1Placebo-Controlled Period: Treatment 2Placebo-Controlled Period: Placebo
Percentage of Participants With an Improvement of ≥ 50% From Baseline in the CLASI-A Score (CLASI-50).60.054.221.7
SecondaryPercentage of Participants Who Have Disease Improvement as Defined by a Reduction in CLASI-A of ≥ 4 Points From Baseline.

The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated clinical tool designed to assess skin involvement in cutaneous lupus erythematosus (CLE). It separately scores: * Disease activity (e.g., erythema, scale, mucous membrane involvement, alopecia) * Damage (e.g., dyspigmentation, scarring) CLASI enables classification of disease severity: Mild: Activity score 0-9 Moderate: 10-20 Severe: 21-70

Time frame:
From first dose to Week 16 (approximately 16 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Have Disease Improvement as Defined by a Reduction in CLASI-A of ≥ 4 Points From Baseline.
Percentage of participantsPlacebo-Controlled Period: Treatment 1Placebo-Controlled Period: Treatment 2Placebo-Controlled Period: Placebo
Percentage of Participants Who Have Disease Improvement as Defined by a Reduction in CLASI-A of ≥ 4 Points From Baseline.60.066.739.1
SecondaryMean Change From Baseline in CLASI-A Score.

The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated clinical tool designed to assess skin involvement in cutaneous lupus erythematosus (CLE). It separately scores: * Disease activity (e.g., erythema, scale, mucous membrane involvement, alopecia) * Damage (e.g., dyspigmentation, scarring) CLASI enables classification of disease severity: Mild: Activity score 0-9 Moderate: 10-20 Severe: 21-70

Time frame:
From first dose to Week 16 (approximately 16 weeks)
Reported as:
Mean · Score on a Scale
Mean Change From Baseline in CLASI-A Score.
Score on a ScalePlacebo-Controlled Period: Treatment 1Placebo-Controlled Period: Treatment 2Placebo-Controlled Period: Placebo
Mean Change From Baseline in CLASI-A Score.-9.8 ± 12.69-7.5 ± 5.92-4.3 ± 5.54
SecondaryPercentage of Participants Who Have a Complete Response (CR) on CLASI-A Defined as a Score of "0".

The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated clinical tool designed to assess skin involvement in cutaneous lupus erythematosus (CLE). It separately scores: * Disease activity (e.g., erythema, scale, mucous membrane involvement, alopecia) * Damage (e.g., dyspigmentation, scarring) CLASI enables classification of disease severity: Mild: Activity score 0-9 Moderate: 10-20 Severe: 21-70 Complete Response (CR) on CLASI-A defined as a score of "0".

Time frame:
From first dose to Week 16 (approximately 16 weeks)
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Have a Complete Response (CR) on CLASI-A Defined as a Score of "0".
Percentage of ParticipantsPlacebo-Controlled Period: Treatment 1Placebo-Controlled Period: Treatment 2Placebo-Controlled Period: Placebo
Percentage of Participants Who Have a Complete Response (CR) on CLASI-A Defined as a Score of "0".12.04.20
SecondaryNumber of Participants With Safety Related Events in the Placebo Controlled Period

Number of participants with safety related events in the placebo controlled period

Time frame:
From signing informed consent to end of safety follow up period (Approximately 60 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Safety Related Events in the Placebo Controlled Period
ParticipantsPlacebo-Controlled Period: Treatment 1Placebo-Controlled Period: Treatment 2Placebo-Controlled Period: Placebo
TEAE171912
Treatment-related TEAEs11113
Serious TEAE221
Treatment related Serious TEAE110
SecondaryNumber of Participants With Safety Related Events in the Active Treatment Period

Number of participants with safety related events in the active treatment period

Time frame:
From signing informed consent to end of safety follow up period (Approximately 60 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Safety Related Events in the Active Treatment Period
ParticipantsPlacebo-Controlled Period: Treatment 1Placebo-Controlled Period: Treatment 2Active-Treatment Period: Treatment 1Active-Treatment Period: Treatment 2
TEAEs111056
Treatment related TEAEs5522
Serious TEAEs1001
Treatment related serious TEAE1000
SecondaryNumber of Participants With Clinically Significant Laboratory Abnormalities in the Placebo Controlled Period

Number of participants with clinically significant laboratory abnormalities in the placebo controlled period

Time frame:
From signing informed consent to end of safety follow up period (Approximately 60 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities in the Placebo Controlled Period
ParticipantsPlacebo-Controlled Period: Treatment 1Placebo-Controlled Period: Treatment 2Placebo-Controlled Period: Placebo
Creatinine Kinase ≥ 2.5x ULN112
Hemoglobin < 9 g/dL (90g/L)100
SecondaryNumber of Participants With Clinically Significant Laboratory Abnormalities in the Active Treatment Period

Number of participants with clinically significant laboratory abnormalities in the active treatment period

Time frame:
From signing informed consent to end of safety follow up period (Approximately 60 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities in the Active Treatment Period
ParticipantsPlacebo-Controlled Period: Treatment 1Placebo-Controlled Period: Treatment 2Active-Treatment Period: Treatment 1Active-Treatment Period: Treatment 2
ALT > 3xULN0010
AST > 3xULN0010
Creatinine Kinase ≥ 2.5x ULN3121
Hemoglobin < 9 g/dL (90g/L)1000
SecondaryNumber of Participants With Clinically Significant Vital Sign Abnormalities in the Placebo Controlled Period

Number of participants with clinically significant vital sign abnormalities in the placebo controlled period

Time frame:
From signing informed consent to end of safety follow up period (Approximately 60 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Vital Sign Abnormalities in the Placebo Controlled Period
ParticipantsPlacebo-Controlled Period: Treatment 1Placebo-Controlled Period: Treatment 2Placebo-Controlled Period: Placebo
Number of Participants With Clinically Significant Vital Sign Abnormalities in the Placebo Controlled Period000
SecondaryNumber of Participants With Clinically Significant Vital Sign Abnormalities in the Active Treatment Period

Number of participants with clinically significant vital sign abnormalities in the active treatment period

Time frame:
From signing informed consent to end of safety follow up period (Approximately 60 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Vital Sign Abnormalities in the Active Treatment Period
ParticipantsPlacebo-Controlled Period: Treatment 1Placebo-Controlled Period: Treatment 2Active-Treatment Period: Treatment 1Active-Treatment Period: Treatment 2
Number of Participants With Clinically Significant Vital Sign Abnormalities in the Active Treatment Period0000
SecondaryNumber of Participants With Clinically Significant ECG Abnormalities in the Placebo Controlled Period

Number of participants with clinically significant ECG abnormalities in the placebo controlled period

Time frame:
From signing informed consent to end of active treatment period (Approximately 56 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant ECG Abnormalities in the Placebo Controlled Period
ParticipantsPlacebo-Controlled Period: Treatment 1Placebo-Controlled Period: Treatment 2Placebo-Controlled Period: Placebo
Number of Participants With Clinically Significant ECG Abnormalities in the Placebo Controlled Period000
SecondaryNumber of Participants With Clinically Significant ECG Abnormalities in the Active Treatment Period

Number of participants with clinically significant ECG abnormalities in the active treatment period

Time frame:
From signing informed consent to end of active treatment period (Approximately 56 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant ECG Abnormalities in the Active Treatment Period
ParticipantsPlacebo-Controlled Period: Treatment 1Placebo-Controlled Period: Treatment 2Active-Treatment Period: Treatment 1Active-Treatment Period: Treatment 2
Number of Participants With Clinically Significant ECG Abnormalities in the Active Treatment Period0000

Adverse events

Collected over AEs/SAEs are collected from the time of signing the consent until post treatment follow up period of 28 days, approximately 13 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo-Controlled Period - DEUC 3 mg BID0/25 (0%)2/25 (8%)15/25 (60%)
Placebo-Controlled Period - DEUC 6 mg BID0/24 (0%)2/24 (8.3%)15/24 (62.5%)
Placebo-Controlled Period - Placebo BID0/24 (0%)1/24 (4.2%)8/24 (33.3%)
Active Treatment Period - DEUC 3 mg BID0/16 (0%)1/16 (6.3%)11/16 (68.8%)
Active Treatment Period - DEUC 6 mg BID0/20 (0%)0/20 (0%)10/20 (50%)
Active Treatment Period - Placebo-DEUC 3 mg BID0/9 (0%)0/9 (0%)5/9 (55.6%)
Active Treatment Period - Placebo-DEUC 6 mg BID0/9 (0%)1/9 (11.1%)6/9 (66.7%)
Most frequent serious events
Most frequent serious events
EventPlacebo-Controlled Period - DEUC 3 mg BIDPlacebo-Controlled Period - DEUC 6 mg BIDPlacebo-Controlled Period - Placebo BIDActive Treatment Period - DEUC 3 mg BIDActive Treatment Period - DEUC 6 mg BIDActive Treatment Period - Placebo-DEUC 3 mg BIDActive Treatment Period - Placebo-DEUC 6 mg BID
Humerus fractureInjury, poisoning and procedural complications0/250/240/240/160/200/91/9
COVID-19Infections and infestations0/250/240/241/160/200/90/9
PyrexiaGeneral disorders0/251/240/240/160/200/90/9
PneumoniaInfections and infestations0/251/240/240/160/200/90/9
Stress urinary incontinenceRenal and urinary disorders0/250/241/240/160/200/90/9
Oral herpesInfections and infestations1/250/240/240/160/200/90/9
Abortion induced incompleteInjury, poisoning and procedural complications1/250/240/240/160/200/90/9
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/250/240/240/160/200/90/9
Most frequent other events
Showing 10 of 114
Most frequent other events
EventPlacebo-Controlled Period - DEUC 3 mg BIDPlacebo-Controlled Period - DEUC 6 mg BIDPlacebo-Controlled Period - Placebo BIDActive Treatment Period - DEUC 3 mg BIDActive Treatment Period - DEUC 6 mg BIDActive Treatment Period - Placebo-DEUC 3 mg BIDActive Treatment Period - Placebo-DEUC 6 mg BID
COVID-19Infections and infestations1/251/240/245/161/202/90/9
LeukopeniaBlood and lymphatic system disorders0/91/40/60/160/200/90/9
PalpitationsCardiac disorders0/91/41/60/160/200/90/9
Eyelid oedemaEye disorders0/91/40/60/160/200/90/9
Oral mucosa erosionGastrointestinal disorders0/91/40/60/160/200/90/9
Oral painGastrointestinal disorders0/91/40/60/160/200/90/9
FatigueGeneral disorders0/91/40/60/160/200/90/9
BacteraemiaInfections and infestations0/91/40/60/160/200/90/9
TendonitisMusculoskeletal and connective tissue disorders0/91/40/60/160/200/90/9
Seborrhoeic keratosisNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/91/40/60/160/200/90/9

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Placebo-Controlled Period: Treatment 1Placebo-Controlled Period: Treatment 2Placebo-Controlled Period: PlaceboTotal
<=18 years0000
Between 18 and 65 years22252168
>=65 years3036
Age, Continuous
Age, Continuous(Years)Placebo-Controlled Period: Treatment 1Placebo-Controlled Period: Treatment 2Placebo-Controlled Period: PlaceboTotal
Mean47.3 ± 15.0642.8 ± 12.1646.2 ± 12.8245.4 ± 13.36
Sex: Female, Male
Sex: Female, Male(Participants)Placebo-Controlled Period: Treatment 1Placebo-Controlled Period: Treatment 2Placebo-Controlled Period: PlaceboTotal
Female17191854
Male86620
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo-Controlled Period: Treatment 1Placebo-Controlled Period: Treatment 2Placebo-Controlled Period: PlaceboTotal
Hispanic or Latino951327
Not Hispanic or Latino16201147
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo-Controlled Period: Treatment 1Placebo-Controlled Period: Treatment 2Placebo-Controlled Period: PlaceboTotal
American Indian or Alaska Native1034
Asian2327
Native Hawaiian or Other Pacific Islander0000
Black or African American46212
White17131343
More than one race0000
Unknown or Not Reported1348
08

Study locations

41 sites
  • Local Institution - 0077
    Scottsdale, Arizona 85259, United States
  • Local Institution - 0076
    Irvine, California 92697, United States
  • Local Institution - 0046
    Los Angeles, California 90045, United States
  • Local Institution - 0073
    Farmington, Connecticut 06030, United States
  • Local Institution - 0082
    Orlando, Florida 32827, United States
  • Local Institution - 0060
    Ann Arbor, Michigan 48109, United States
  • Local Institution - 0059
    St Louis, Missouri 63108, United States
  • Local Institution - 0037
    New York, New York 10029, United States
  • Local Institution - 0065
    Durham, North Carolina 27713, United States
  • Local Institution - 0067
    Columbus, Ohio 43215, United States
  • Local Institution - 0026
    Oklahoma City, Oklahoma 73104, United States
  • Local Institution - 0054
    Charleston, South Carolina 29407, United States
  • Local Institution - 0018
    Capital Federal, Buenos Aires 1023, Argentina
  • Local Institution - 0013
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Local Institution - 0019
    Buenos Aires, 1431, Argentina
  • Local Institution - 0003
    Botany, New South Wales 2019, Australia
  • Local Institution - 0001
    Kogarah, New South Wales 2217, Australia
  • Local Institution - 0002
    Camberwell, Victoria 3124, Australia
  • Local Institution - 0007
    Clayton, Victoria 0, Australia
  • Local Institution - 0078
    Melbourne, Victoria 3004, Australia
  • Local Institution - 0087
    Victoria Park, Western Australia 6100, Australia
  • Local Institution - 0038
    Bordeaux, 33075, France
  • Local Institution - 0027
    Créteil, 94000, France
  • Local Institution - 0010
    Paris, 75970, France
  • Local Institution - 0072
    Dresden, Saxony 01307, Germany
  • Local Institution - 0035
    Berlin, 10117, Germany
  • Local Institution - 0014
    Erlangen, 91054, Germany
  • Local Institution - 0006
    Hamburg, 22391, Germany
  • Local Institution
    Guadalajara, Jalisco 45030, Mexico
  • Local Institution - 0058
    Zapopan, Jalisco 45070, Mexico
  • Local Institution - 0036
    Monterrey, Nuevo León 64718, Mexico
  • Local Institution - 0029
    Aguascalientes, 20130, Mexico
  • Local Institution - 0028
    Guadalajara, 0, Mexico
  • Local Institution - 0071
    Mexico City, 14080, Mexico
  • Local Institution - 0005
    Rzeszów, 35-055, Poland
  • Local Institution - 0009
    Wroclaw, 50-566, Poland
  • Local Institution - 0008
    Lodz, Łódź Voivodeship 94-046, Poland
  • Local Institution - 0031
    Kaohsiung City, 833, Taiwan
  • Local Institution - 0023
    Taichung, 402, Taiwan
  • Local Institution - 0021
    Taichung, 404, Taiwan
  • Local Institution - 0022
    Taipei, 10051, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Aug 2024, 37 months.

Results were first posted in Sep 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2021
First posted
Apr 23, 2021
StartActual
Jul 12, 2021
Primary completionActual
Aug 22, 2024
CompletionEst.
Feb 28, 2028
Results first posted
Sep 10, 2025
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04857034
Responsible party
Sponsor
First posted
Apr 23, 2021
Start date
Jul 12, 2021
Primary completion
Aug 22, 2024
Completion
Feb 28, 2028 (estimated)
Results posted
Sep 10, 2025
Last update
Sep 10, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion